E-DRUG: Oxford Quality Statement and call to action in the Lancet
-----------------------------------------------------------------
Dear E-Druggers,
You will remind that 23-28 September 2018 the first ever conference on Medicines Quality and Public Health took place in Oxford. It brought together people from a diversity of sectors working in this field, such as public health, national regulatory authorities, pharmacy, biomedical, chemistry, law, ethics, cultural and social sciences, the pharmaceutical industry, international organizations, NGOs, national procurement centres, and internet and pharmaceutical forensics.
The Oxford statement was released shortly after the conference: https://www.tropicalmedicine.ox.ac.uk/events/medicine-quality/mqph2018/oxford-statement
Today, a longer Oxford Statement has been published in the Lancet Global Health:
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30426-7/fulltext
We warmly recommend reading it, for all those with some interest and / or involvement in this field. It is supported by 156 signatories [with many E-druggers, including your moderator!} from a variety of fields, expertise, roles and regions, and it expands the previous short statement with a call to action and a research agenda. These actions will require advocacy and political commitment spanning diverse sectors, , as well as partnerships across key-stakeholders including regulators; Ministries of Health, Finance and Trade, and Science and Technology; pharmaceutical manufacturers and distributors; medicine procurers; funding and implementation agencies; central medical stores; pharmacists; innovators; academics; law enforcement agencies; the judiciary; and civil society, including patients' organisations. We hope that you can help us to circulate it in your organizations and in your respective countries!
Research agenda: https://www.thelancet.com/cms/10.1016/S2214-109X(19)30426-7/attachment/fed581a4-e1c7-4b67-8aea-1bc4f2b4bd31/mmc1.pdf
Co-signatories list: see https://www.thelancet.com/cms/10.1016/S2214-109X(19)30426-7/attachment/504c2409-23fd-4b65-b62a-43bb168cf0b1/mmc2.pdf
with kind regards
Rafaella
Raffaella Ravinetto, PharmD, PhD
Medicines Research & Networking
Tel: +3232476625
rravinetto@itg.be / www.itg.be